

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
22 April 2004 (22.04.2004)

PCT

(10) International Publication Number  
**WO 2004/032882 A3**

(51) International Patent Classification: **C07D 263/30**,  
A61K 31/421

(21) International Application Number:  
PCT/US2003/033317

(22) International Filing Date: 10 October 2003 (10.10.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/417,548 10 October 2002 (10.10.2002) US

(71) Applicant (for all designated States except US):  
**SMITHKLINE BEECHAM CORPORATION**  
[US/US]; One Franklin Plaza, Philadelphia, PA 19101  
(US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BROWN, Matthew**,  
Lee [US/US]; c/o GlaxoSmithKline, Five Moore Drive,  
PO Box 13398, Research Triangle Park, NC 27709 (US).  
**CHEUNG, Mui** [CN/US]; c/o GlaxoSmithKline, Five  
Moore Drive, PO Box 13398, Research Triangle Park, NC  
27709 (US). **DICKERSON, Scott, Howard** [US/US];  
c/o GlaxoSmithKline, Five Moore Drive, PO Box 13398,  
Research Triangle Park, NC 27709 (US). **GAUTHIER**,  
**Cassandra** [US/US]; c/o GlaxoSmithKline, Five Moore  
Drive, PO Box 13398, Research Triangle Park, NC 27707  
(US). **HARRIS, Philip, Anthony** [GB/US]; c/o Glaxo-  
SmithKline, Five Moore Drive, PO Box 13398, Research  
Triangle Park, NC 27709 (US). **HUNTER, Robert, Nell**,  
III [US/US]; c/o GlaxoSmithKline, Five Moore Drive,  
PO Box 13398, Research Triangle Park, NC 27709 (US).  
**PACOFISKY, Gregory** [US/US]; 510 Polk Street, Raleigh,  
NC 27604 (US). **PEEL, Michael, Robert** [GB/US]; c/o  
GlaxoSmithKline, Five Moore Drive, PO Box 13398,

Research Triangle Park, NC 27709 (US). **STAFFORD**,  
**Jeffrey, Alan** [US/US]; c/o GlaxoSmithKline, Five Moore  
Drive, PO Box 13398, Research Triangle Park, NC 27709  
(US).

(74) Agents: **LEVY, David, J. et al.**; c/o GlaxoSmithKline,  
Corporate Intellectual Property Department, Five Moore  
Drive, PO Box 13398, Research Triangle Park, NC 27709  
(US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,  
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,  
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,  
MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT,  
RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,  
TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

(88) Date of publication of the international search report:  
8 July 2004

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: **CHEMICAL COMPOUNDS**

(57) Abstract: Oxazole derivatives, which are useful as VEGFR2, CDK2, and CDK4 inhibitors are described herein. The described invention also includes methods of making such oxazole derivatives as well as methods of using the same in the treatment of hyper-proliferative diseases.

WO 2004/032882 A3